Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.

Tuberculosis (Edinburgh, Scotland) - 1 Jul 2017

Bax Hannelore I, Bakker-Woudenberg Irma A J M, de Vogel Corné P, van der Meijden Aart, Verbon Annelies, de Steenwinkel Jurriaan E M

Abstract excerpt

Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical models assessing anti-tuberculosis drug activity are available, but it is yet unclear which combination of models is most predictive of clinical treatment efficacy. The aim of this study was to determine the role of our in vitro time kill-kinetics assay as an asset to a predictive preclinical modeling framework assessing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Bacterial Load

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Drug Synergism

Share to Drug Therapy, Combination

Share to Microbial Viability

Share to Mycobacterium tuberculosis

Share to Tuberculosis

Source

Identifiers

PMID: 28610791
DOI: 10.1016/j.tube.2017.04.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.PMID 28610791Read ↗

Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approachSemantic proximity Read ↗

<scp>TB</scp> drug development: immunology at the tableSemantic proximity Read ↗

Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.Semantic proximity Read ↗

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosisSemantic proximity Read ↗

In Silico Strategies in Tuberculosis Drug DiscoverySemantic proximity Read ↗

Drug susceptibility of the Mycobacterium genus: in vitro tests and clinical implications.Semantic proximity Read ↗

A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugsSemantic proximity Read ↗

A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts <i>in vivo</i> interactions of tuberculosis drugsSemantic proximity Read ↗

Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screeningSemantic proximity Read ↗

Systematic measurement of combination drug landscapes to predict <i>in vivo</i> treatment outcomes for tuberculosisSemantic proximity Read ↗

Implementing Best Practises on Data Generation and Reporting of <i>Mycobacterium tuberculosis</i> Time Kill Assays: A Case Study of Standardized Protocol Within the ERA4TB ConsortiumSemantic proximity Read ↗

Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.